NASDAQ:ALDX Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free ALDX Stock Alerts $4.09 -0.08 (-1.92%) (As of 11:37 AM ET) Add Compare Share Share Today's Range$4.07▼$4.1750-Day Range$2.77▼$4.7252-Week Range$1.42▼$11.97Volume62,113 shsAverage Volume556,382 shsMarket Capitalization$243.00 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aldeyra Therapeutics alerts: Email Address Aldeyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside128.2% Upside$9.33 Price TargetShort InterestBearish4.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 11 Articles This WeekInsider TradingAcquiring Shares$1.47 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.14) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.64 out of 5 starsMedical Sector647th out of 905 stocksPharmaceutical Preparations Industry297th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Aldeyra Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.17% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Aldeyra Therapeutics has recently increased by 15.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 1.7 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Aldeyra Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 16 people have searched for ALDX on MarketBeat in the last 30 days. This is a decrease of -11% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have bought 303.41% more of their company's stock than they have sold. Specifically, they have bought $1,473,245.00 in company stock and sold $365,194.00 in company stock.Percentage Held by InsidersOnly 7.30% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aldeyra Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -8.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 2.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aldeyra Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About Aldeyra Therapeutics Stock (NASDAQ:ALDX)Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More ALDX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALDX Stock News HeadlinesApril 9, 2024 | insidertrades.comPerceptive Advisors Llc Purchases 37,712 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockMay 8, 2024 | businesswire.comAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.May 8, 2024 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Reaffirmed by HC WainwrightMay 8, 2024 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Reaffirmed by OppenheimerMay 7, 2024 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Downgraded to Sell at StockNews.comMay 3, 2024 | investorplace.comALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024April 30, 2024 | americanbankingnews.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest UpdateMay 8, 2024 | Behind the Markets (Ad)Could this Tiny Biotech End Disease Forever?Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.April 25, 2024 | businesswire.comAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayApril 18, 2024 | businesswire.comAldeyra Therapeutics to Host Research & Development Day on April 25, 2024April 15, 2024 | markets.businessinsider.comAttention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors: Grabar Law Office Is Investigating Claims on Your BehalfApril 10, 2024 | investing.comPerceptive advisors buys Aldeyra Therapeutics shares worth $833kApril 4, 2024 | msn.comAldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingApril 3, 2024 | msn.comAldeyra gains as Oppenheimer upgrades on revised plans for lead assetApril 3, 2024 | finance.yahoo.comAldeyra's Dry Eye Disease Drug May Be on Path for FDA ApprovalApril 3, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The CornerApril 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)March 13, 2024 | finance.yahoo.comAldeyra Therapeutics Inc President and CEO Todd Brady Sells Company SharesMarch 11, 2024 | markets.businessinsider.comStrong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic PartnershipsFebruary 22, 2024 | finance.yahoo.comInstitutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the companyFebruary 14, 2024 | cnn.comIntellia Therapeutics, Inc.February 6, 2024 | finance.yahoo.comAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | benzinga.comAldeyra Therapeutics Stock (NASDAQ:ALDX), Guidance and ForecastJanuary 28, 2024 | seekingalpha.comWhy Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's ProspectsJanuary 4, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Aldeyra Therapeutics, Inc. (ALDX)January 4, 2024 | finance.yahoo.comAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesSee More Headlines Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+127.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.69% Return on Assets-20.26% Debt Debt-to-Equity RatioN/A Current Ratio6.50 Quick Ratio6.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book2.01Miscellaneous Outstanding Shares59,410,000Free Float55,077,000Market Cap$244.18 million OptionableOptionable Beta1.45 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsWerewolf TherapeuticsNASDAQ:HOWL2seventy bioNASDAQ:TSVT23andMeNASDAQ:MEFoghorn TherapeuticsNASDAQ:FHTXImmutepNASDAQ:IMMPView All CompetitorsInsiders & InstitutionsBNP Paribas Financial MarketsBought 4,797 shares on 5/1/2024Ownership: 0.043%Simplex Trading LLCSold 5,300 shares on 4/25/2024Ownership: 0.000%Denali Advisors LLCBought 47,300 shares on 4/19/2024Ownership: 0.080%Kingswood Wealth Advisors LLCBought 15,000 shares on 4/15/2024Ownership: 0.025%Woodstock CorpBought 54,011 shares on 4/9/2024Ownership: 0.290%View All Insider TransactionsView All Institutional Transactions ALDX Stock Analysis - Frequently Asked Questions Should I buy or sell Aldeyra Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks. What is Aldeyra Therapeutics' stock price target for 2024? 3 brokerages have issued 1 year target prices for Aldeyra Therapeutics' shares. Their ALDX share price targets range from $8.00 to $10.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 128.2% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts. How have ALDX shares performed in 2024? Aldeyra Therapeutics' stock was trading at $3.51 at the beginning of the year. Since then, ALDX shares have increased by 16.5% and is now trading at $4.09. View the best growth stocks for 2024 here. Are investors shorting Aldeyra Therapeutics? Aldeyra Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 2,360,000 shares, an increase of 15.1% from the March 31st total of 2,050,000 shares. Based on an average daily trading volume, of 584,200 shares, the days-to-cover ratio is currently 4.0 days. Currently, 4.2% of the shares of the company are short sold. View Aldeyra Therapeutics' Short Interest. When is Aldeyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ALDX earnings forecast. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.13. What ETF holds Aldeyra Therapeutics' stock? Invesco Nasdaq Future Gen 200 ETF holds 11,339 shares of ALDX stock, representing 0.62% of its portfolio. What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). Who are Aldeyra Therapeutics' major shareholders? Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.65%), Woodstock Corp (0.29%), Denali Advisors LLC (0.08%), BNP Paribas Financial Markets (0.04%), Kingswood Wealth Advisors LLC (0.03%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bruce Greenberg, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALDX) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.